
ZAZZI MAURIZIO
Office hours
-
Monday from 16:00 to 18:00Place: Studio del docente - Policlinico "Le Scotte"Note: Solo previo appuntamento a mezzo e-mail.
Contacts
Teaching activities
Completion accademic year: 2023/2024
Completion accademic year: 2022/2023
Completion accademic year: 2021/2022
Research
Ultime pubblicazioni:
- Saladini, F., Giammarino, F., Maggiolo, F., Ferrara, M., Cenderello, G., Celesia, B.M., et al. (2023). Residual phenotypic susceptibility to doravirine in multidrug resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 106737 [10.1016/j.ijantimicag.2023.106737]. - view more
- Rhee, S., Schapiro, J.M., Saladini, F., Zazzi, M., Khoo, S., Shafer, R.W. (2023). Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance. AIDS RESEARCH AND THERAPY, 20(1), 1-7 [10.1186/s12981-023-00503-5]. - view more
- Marchi, S., Dragoni, F., Boccuto, A., Idoko, O.T., Zazzi, M., Sow, S., et al. (2023). Neutralizing activity of African lineage Zika virus immune sera towards Asian lineage. ACTA TROPICA, 237, 106736 [10.1016/j.actatropica.2022.106736]. - view more
- Kuznetsova, A., Lebedev, A., Gromov, K., Kazennova, E., Zazzi, M., Incardona, F., et al. (2022). Pre-existing singleton E138A mutations in the reverse transcriptase gene do not affect the efficacy of first-line antiretroviral therapy regimens using rilpivirine in human immunodeficiency virus-infected patients. CLINICAL CASE REPORTS, 10(2), e05373 [10.1002/ccr3.5373]. - view more
- Rossetti, B., Ferrara, M., Taramasso, L., Bai, F., Lombardi, F., Ciccarelli, N., et al. (2022). THE EFFECTS OF SWITCHING FROM DOLUTEGRAVIR/ABACAVIR/LAMIVUDINE TO BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE IN VIROLOGICALLY SUPPRESSED PEOPLE LIVING WITH HIV ON NEUROPSYCHIATRIC SYMPTOMS: PRELIMINARY FINDINGS FROM A RANDOMIZED STUDY. In Atti al 14th Congresso ICAR 2022 (Italian Conference on AIDS and Antiviral Research). - view more